Transmural Biotech, the biotech company in the ASISA group, has completed the process established by European regulations for the marketing of quantusMM, a non-invasive test based on artificial intelligence (AI) which permits the diagnosis of breast diseases, including breast cancer, with 92% accuracy, using images obtained from breast scans. Obtaining CE marking is a key step in developing this technology, as it is also valid for most Asian and Latin American countries. In the case...